Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
February 22, 2022 12:40 PM EST
RBC Capital analyst Brian Abrahams weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) amid the recent turbulence in the stock, including the 20% up move on Friday on the conference cancellation, which triggered M&A speculation, and today's 31% downdraft on the departure of CMO Dr. Jatin... More
February 22, 2022 9:20 AM EST
Pre-Open Stock Movers:
Meritor, Inc. (NYSE: MTOR) 44.5% HIGHER; Cummins Inc. (NYSE:... More
February 22, 2022 7:12 AM EST
(Updated - February 22, 2022 7:23 AM EST)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity.
"As accomplished leaders with proven track... More
February 18, 2022 10:15 AM EST
Karyopharm Therapeutics (NASDAQ: KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg, Citing Email
...
More
February 18, 2022 9:37 AM EST
(Updated - February 18, 2022 9:41 AM EST)
Karyopharm Therapeutics (NASDAQ: KPTI) shares gain 13% in early trading, bucking market weakness.
gains tied to news the company canceled from today's fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. This was said...
More
